

Table 1: TR02 Mean Reduction in Worst itch NRS During the Evaluation Period (MITT Population)

Mean (SD) NRS [†] Data	NAL 60	NAL 120	Placebo
N (number of patients)	128	120	123
Baseline	N=128 6.87 (1.40)	N=120 6.94 (1.46)	N=123 6.75 (1.37)
Evaluation Period (Observed Cases)	N=82 3.97 (2.52)	N=84 3.51 (2.11)	N=108 4.03 (2.48)
Change from Baseline	-3.10 (2.35)	-3.49 (2.37)	-2.80 (2.22)
LS Mean Difference from Placebo	-0.24	-0.73	
p-value vs Placebo	0.432	0.017*	

*statistical significance defined per protocol as p-value ≤ 0.05 based step-down analysis specification; initial comparison of NAL 120 vs. placebo based on least square (LS) means
Modified Intent-to-Treat Population